secwatch.observer — SEC 8-K summary
======================================

Issuer:     Traws Pharma, Inc. (TRAW)
CIK:        0001130598
Form:       8-K
Filed at:   2026-08-14T20:30:44+00:00
Accession:  0001104659-26-097226
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Traws Pharma Q2 2026 net loss $3.0M, no revenue; cash $5.0M, runway into Q1 2027
--------------------------------------------------------------------------------

- Q2 2026 net loss $3.0M ($0.16/share) vs $0.9M loss in Q2 2025; no revenue vs $2.7M prior.
- Cash $5.0M at June 30, 2026 vs $3.8M at Dec 31, 2025; expects runway into Q1 2027, may need more financing.
- MHRA resubmission for tivoxavir marboxil expected Q3 2026; FDA clinical hold still unresolved, response planned by end 2026.
- April 2026 financing delivered $10M upfront, potential $50M via warrants; shareholders approved Series B and C on July 8, 2026.
- Six-month net loss $10.2M vs net income $20.6M in 2025 (due to $26.7M warrant gain).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130598/000110465926097226/0001104659-26-097226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130598/000110465926097226/tm2623190d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-097226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer